AI-driven molecular generation powered by STRING v12.0protein interaction networks protein interaction networks,, ColabDesignAI molecular generation framework structure-aware optimization, and active learning loops that converge on viable drug candidates with RDKitcomputational chemistry-validated ADMET profiles.
We mine the STRING v12.0protein interaction database of protein-protein interactions to identify druggable nodes, then generate novel molecular scaffolds optimized for those targets.
Structure-aware molecular generation using ColabDesign'sour differentiable protein design framework, accelerated by JAXXLA on TPU/GPU and PyTorchdeep learning frameworks on GPU.
Differentiable protein design with structure prediction in the loop. Generates sequences optimized for binding affinity, stability, and specificity.
XLA-compiled gradient computation on TPU v4 pods for large-scale conformational sampling. Automatic vectorization across candidate batches.
GPU compute for local rapid prototyping. Real-time molecular property prediction on dedicated GPU hardware.
Our iterative design loop uses uncertainty-guided sampling to efficiently explore chemical space. Each cycle narrows the candidate pool while improving predictive confidence.
Every generated molecule passes through rigorous computational chemistry validation. Lipinski's Rule of Five, synthetic accessibility scoring, and ADMET property prediction ensure only viable candidates advance.
| Metric | Threshold | Batch Average | Pass Rate | Status |
|---|---|---|---|---|
| Molecular Weight | ≤ 500 Da | 387.4 Da | 94.2% | Pass |
| LogP | ≤ 5.0 | 2.87 | 91.8% | Pass |
| H-Bond Donors | ≤ 5 | 2.1 | 97.3% | Pass |
| H-Bond Acceptors | ≤ 10 | 5.4 | 96.1% | Pass |
| SA Score | ≤ 4.0 | 3.2 | 88.5% | Monitor |
| QED Score | ≥ 0.5 | 0.72 | 93.6% | Pass |
We present a novel framework integrating STRING v12.0large-scale protein-protein interaction networks with differentiable molecular generation via ColabDesignAI molecular generation. Our active learning loop achieves 3.2x faster convergence than random sampling baselines while maintaining 94.2% Lipinski compliance across 3,529 generated candidates.
From target identification to validated drug candidates. Let our AI-driven de novo design pipeline accelerate your discovery program.